{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-111931","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.266266+00:00","generated_at":"2026-05-16T19:53:03.462038+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Scholar Rock Q3 net loss $102.2M; Type A FDA meeting positive for apitegromab BLA resubmission in 2026","bullets":["Net loss $102.2M (EPS -$0.90) vs $64.5M (EPS -$0.66) YoY; no revenue.","Cash $369.6M; plus ~$60M from warrants expiring Dec 31, 2025, expected to fund into 2027.","Type A meeting with FDA completed Nov 12; BLA resubmission and U.S. launch for apitegromab in SMA anticipated in 2026.","Second U.S. fill-finish facility secured; commercial capacity reserved starting Q1 2026.","FDA cleared IND for SRK-439; dosing in healthy volunteers to begin Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-111931","json":"https://secwatch.observer/filing/0001104659-25-111931.json","markdown":"https://secwatch.observer/filing/0001104659-25-111931.md","text":"https://secwatch.observer/filing/0001104659-25-111931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/0001104659-25-111931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/srrk-20251114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:53:03.462038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}